Literature DB >> 33361650

Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.

Akiko Yuno1, Yoshiyuki Kenmotsu1, Yuka Takahashi2, Hiroshi Nomoto2, Hiraku Kameda2, Kyu Yong Cho2, Akinobu Nakamura2, Yu Yamashita3, Junichi Nakamura3, Sho Nakakubo3, Keisuke Kamada3, Masaru Suzuki3, Hirokazu Sugino4, Naoko Inoshita5, Satoshi Konno3, Hideaki Miyoshi6, Tatsuya Atsumi2, Yutaka Sawamura7, Akira Shimatsu8.   

Abstract

We provide the details of the successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. The patient was a 27-year-old Japanese female healthcare worker who was scheduled to undergo pituitary surgery for Cushing's disease. She had been in close contact with an undiagnosed patient infected with COVID-19 and then developed COVID-19 pneumonia. Despite a lack of known risk factors associated with severe COVID-19 infection, the patient's dyspnea worsened and her respiratory condition deteriorated, as indicated by the need for 7 L/min oxygen supply by mask to maintain her oxygen saturation at >90%. Medical treatment was initiated to control hypercortisolism by the 'block and replace' regimen using steroidogenesis inhibitors and hydrocortisone. The COVID-19 pneumonia improved with multi-modal treatment including antiviral therapy. One month later, after a negative severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) test result and with appropriate protection against virus transmission to medical staff in the operating room and daily medical care nurses, trans-sphenoidal surgery was performed by our highly experienced pituitary surgeon. One month after the surgery, the patient's basal ACTH and cortisol levels and urinary free cortisol were all under the detection limit. Surgical remission was expected. Since hypercortisolism due to active Cushing's disease may worsen a COVID-19 infection, multi-disciplinary management that includes appropriate and prompt treatment strategies is mandatory in such cases.

Entities:  

Keywords:  Block and replace regimen; COVID-19; Coronavirus disease 2019; Cushing’s disease; Medical management

Year:  2020        PMID: 33361650     DOI: 10.1507/endocrj.EJ20-0613

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

Review 1.  Successful Immunomodulatory Treatment of COVID-19 in a Patient With Severe ACTH-Dependent Cushing's Syndrome: A Case Report and Review of Literature.

Authors:  Bojana Popovic; Aleksandra Radovanovic Spurnic; Jelena Velickovic; Aleksandra Plavsic; Milica Jecmenica-Lukic; Tijana Glisic; Dusan Ilic; Danka Jeremic; Jelena Vratonjic; Vladimir Samardzic; Zoran Gluvic; Tatjana Adzic-Vukicevic
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-22       Impact factor: 6.055

Review 2.  The Relationship between COVID-19 and Hypothalamic-Pituitary-Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess-The CAPISCO International Expert Panel.

Authors:  Mojca Jensterle; Rok Herman; Andrej Janež; Wael Al Mahmeed; Khalid Al-Rasadi; Kamila Al-Alawi; Maciej Banach; Yajnavalka Banerjee; Antonio Ceriello; Mustafa Cesur; Francesco Cosentino; Massimo Galia; Su-Yen Goh; Sanjay Kalra; Peter Kempler; Nader Lessan; Paulo Lotufo; Nikolaos Papanas; Ali A Rizvi; Raul D Santos; Anca P Stoian; Peter P Toth; Vijay Viswanathan; Manfredi Rizzo
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 3.  COVID-19 and the pituitary.

Authors:  Stefano Frara; Agnese Allora; Laura Castellino; Luigi di Filippo; Paola Loli; Andrea Giustina
Journal:  Pituitary       Date:  2021-05-03       Impact factor: 3.599

Review 4.  Pituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting.

Authors:  Maria Fleseriu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

Review 5.  New Insights on Effects of Glucocorticoids in Patients With SARS-CoV-2 Infection.

Authors:  Elena Chertok Shacham; Avraham Ishay
Journal:  Endocr Pract       Date:  2022-07-21       Impact factor: 3.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.